

Federal R&D Tax Credit Received

PERTH, Australia, 11th January 2018: Phylogica Limited (ASX:PYC) (**Phylogica** or the **Company**), advises that it has received a \$2,170,000 cash refund under the Federal Government's R&D Tax Incentive Scheme.

The refund relates to the costs of research and development during the 2017 Financial Year which qualify as eligible R&D expenditure under the Federal Government's Scheme.

The funds received will be used to advance Phylogica's drug discovery research and development, utilising the Company's Phylomer® peptide libraries and proprietary screening capabilities.

ENDS

For further information, please contact:

INVESTORS

Stephanie Unwin

CEO

stephanieu@phylogica.com

0411 132 287

MEDIA

Ben Walsh

WE Buchan

bwalsh@buchanwe.com.au

0411 520 012

About Phylogica

Phylogica Limited (ASX: PYC) is a biotech company focused on commercialising its intracellular drug delivery platform and panning its Phylomer libraries to identify drug cargoes for development against a wide range of disease targets. Phylogica controls access to the world's most structurally diverse source of peptides called Phylomers, which have the ability to act as effective drug delivery agents and drug cargoes, penetrating cell walls to reach previously 'undruggable' targets across a range of disease types. Phylogica's platform of proprietary cell penetration peptides is showing promise in delivering a diverse range of drug cargoes into cells, and the company's lead asset program has identified a phylomer which can inhibit Myc, a protein responsible for the regulation of cancer cell growth. The company has had collaborations with several pharmaceutical companies including Roche, Medimmune, Pfizer, Janssen and is currently working with Genentech.

Tel: +61 8 9384 3284 | Fax: +61 8 9284 3801

www.phylogica.com

Phylogica Ltd

ABN 48 098 391 961